Benitec Biopharma Ltd Stock Analysis
| BNTC Stock | USD 12.71 1.30 11.39% |
Benitec Biopharma Ltd is undervalued with Real Value of 14.89 and Target Price of 24.0. The main objective of Benitec Biopharma stock analysis is to determine its intrinsic value, which is an estimate of what Benitec Biopharma Ltd is worth, separate from its market price. There are two main types of Benitec Biopharma's stock analysis: fundamental analysis and technical analysis.
The Benitec Biopharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Benitec Biopharma's ongoing operational relationships across important fundamental and technical indicators.
Benitec |
Benitec Stock Analysis Notes
About 46.0% of the company shares are held by institutions such as insurance companies. The book value of Benitec Biopharma was currently reported as 4.68. The company recorded a loss per share of 5.51. Benitec Biopharma last dividend was issued on the 18th of November 2019. The entity had 1:17 split on the 26th of July 2023. Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company was incorporated in 1995 and is headquartered in Hayward, California. Benitec Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 18 people. For more info on Benitec Biopharma Ltd please contact the company at 510 780 0819 or go to https://benitec.com.Benitec Biopharma Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Benitec Biopharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Benitec Biopharma Ltd or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Benitec Biopharma is way too risky over 90 days horizon | |
| Benitec Biopharma appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 216 K. Net Loss for the year was (21.75 M) with profit before overhead, payroll, taxes, and interest of 75 K. | |
| Benitec Biopharma Ltd currently holds about 4.06 M in cash with (19.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5. | |
| Benitec Biopharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Benitec Biopharma to Participate in Upcoming Conferences in March |
Benitec Biopharma Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Benitec Biopharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Benitec Largest EPS Surprises
Earnings surprises can significantly impact Benitec Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-15 | 2023-03-31 | -0.2 | -0.16 | 0.04 | 20 | ||
2024-11-11 | 2024-09-30 | -0.55 | -0.4753 | 0.0747 | 13 | ||
2023-02-13 | 2022-12-31 | -0.11 | -0.2 | -0.09 | 81 |
Benitec Biopharma Environmental, Social, and Governance (ESG) Scores
Benitec Biopharma's ESG score is a quantitative measure that evaluates Benitec Biopharma's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Benitec Biopharma's operations that may have significant financial implications and affect Benitec Biopharma's stock price as well as guide investors towards more socially responsible investments.
Benitec Stock Institutional Investors
| Shares | Lion Point Capital, Lp | 2024-12-31 | 62 K | Myda Advisors Llc | 2024-12-31 | 50 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 42.4 K | Northern Trust Corp | 2024-12-31 | 38.2 K | 683 Capital Management Llc | 2024-12-31 | 35.8 K | Ameriprise Financial Inc | 2024-12-31 | 35.5 K | Susquehanna International Group, Llp | 2024-12-31 | 24.8 K | Qube Research & Technologies | 2024-12-31 | 20.9 K | State Street Corp | 2024-12-31 | 16.1 K | Suvretta Capital Management, Llc | 2024-12-31 | 9 M | Franklin Resources Inc | 2024-12-31 | 2.9 M |
Benitec Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 215.39 M.Benitec Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.48) | (0.50) | |
| Return On Capital Employed | (0.55) | (0.57) | |
| Return On Assets | (0.48) | (0.50) | |
| Return On Equity | (0.53) | (0.56) |
Management Efficiency
Benitec Biopharma has return on total asset (ROA) of (0.496) % which means that it has lost $0.496 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9168) %, meaning that it created substantial loss on money invested by shareholders. Benitec Biopharma's management efficiency ratios could be used to measure how well Benitec Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of February 28, 2025, Return On Tangible Assets is expected to decline to -0.5. In addition to that, Return On Capital Employed is expected to decline to -0.57. At present, Benitec Biopharma's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 147.3 K, whereas Non Current Assets Total are forecasted to decline to about 583.5 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.35 | 3.18 | |
| Tangible Book Value Per Share | 3.35 | 3.18 | |
| Enterprise Value Over EBITDA | (2.69) | (2.83) | |
| Price Book Value Ratio | 2.25 | 2.13 | |
| Enterprise Value Multiple | (2.69) | (2.83) | |
| Price Fair Value | 2.25 | 2.13 | |
| Enterprise Value | 77.4 M | 118.3 M |
Understanding the operational decisions made by Benitec Biopharma management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Technical Drivers
As of the 28th of February, Benitec Biopharma shows the Mean Deviation of 3.65, downside deviation of 4.15, and Risk Adjusted Performance of 0.0756. Benitec Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Benitec Biopharma Price Movement Analysis
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Benitec Biopharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Benitec Biopharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Benitec Biopharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Benitec Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Benitec Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Benitec Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Benitec Biopharma Outstanding Bonds
Benitec Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Benitec Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Benitec bonds can be classified according to their maturity, which is the date when Benitec Biopharma Ltd has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Benitec Biopharma Predictive Daily Indicators
Benitec Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Benitec Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Benitec Biopharma Corporate Filings
10Q | 14th of February 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 13th of February 2025 Other Reports | ViewVerify | |
| 27th of January 2025 Other Reports | ViewVerify | |
F3 | 3rd of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 31st of December 2024 An amendment to a previously filed Form 8-K | ViewVerify |
F4 | 26th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 11th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Benitec Biopharma Forecast Models
Benitec Biopharma's time-series forecasting models are one of many Benitec Biopharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Benitec Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Benitec Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Benitec Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Benitec shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Benitec Biopharma. By using and applying Benitec Stock analysis, traders can create a robust methodology for identifying Benitec entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (119.10) | (125.05) | |
| Operating Profit Margin | (119.74) | (125.73) | |
| Net Loss | (115.80) | (121.59) | |
| Gross Profit Margin | 0.57 | 0.60 |
Current Benitec Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Benitec analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Benitec analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 24.0 | Strong Buy | 7 | Odds |
Most Benitec analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Benitec stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Benitec Biopharma, talking to its executives and customers, or listening to Benitec conference calls.
Benitec Stock Analysis Indicators
Benitec Biopharma Ltd stock analysis indicators help investors evaluate how Benitec Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Benitec Biopharma shares will generate the highest return on investment. By understating and applying Benitec Biopharma stock analysis, traders can identify Benitec Biopharma position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 2.5 M | |
| Common Stock Shares Outstanding | 4.1 M | |
| Total Stockholder Equity | 47.2 M | |
| Property Plant And Equipment Net | 449 K | |
| Cash And Short Term Investments | 50.9 M | |
| Cash | 50.9 M | |
| Accounts Payable | 1.4 M | |
| Net Debt | -50.6 M | |
| 50 Day M A | 9.7691 | |
| Total Current Liabilities | 4.9 M | |
| Other Operating Expenses | 22.5 M | |
| Non Current Assets Total | 536 K | |
| Non Currrent Assets Other | 87 K | |
| Stock Based Compensation | 830 K |
Complementary Tools for Benitec Stock analysis
When running Benitec Biopharma's price analysis, check to measure Benitec Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Benitec Biopharma is operating at the current time. Most of Benitec Biopharma's value examination focuses on studying past and present price action to predict the probability of Benitec Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Benitec Biopharma's price. Additionally, you may evaluate how the addition of Benitec Biopharma to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |